Nordicus Partners NORD

Nordicus Partners Corporation is a U. S. publicly listed biotech company focused on developing breakthrough therapeutics for diseases with unmet medical needs, beginning with oral disorders. The company specializes in acquiring and advancing early-stage life sciences companies from the Nordic region, leveraging the area’s strong scientific ecosystem and drug discovery capabilities. Nordicus targets preclinical biotechnology firms developing treatments for high-growth markets with significant medical needs, aiming to take their drug candidates through Phase I clinical trials before pursuing strategic exits or partnerships. The company’s approach emphasizes value creation through a four-step process involving scouting, accelerating, acquiring, and exiting portfolio companies at premium multiples.

Nordicus Partners Corporation generates revenue primarily through the potential future commercialization of therapeutics developed by its subsidiary companies, as it currently has no marketed products or ongoing revenue streams from sales. The company’s value creation model relies on advancing drug candidates through preclinical and early clinical stages, with the intent to monetize via sale, merger, strategic partnership, or initial public offering of its subsidiaries. Revenue generation is expected to occur upon successful clinical milestones and subsequent transactions involving its portfolio companies, such as Orocidin A/S and Bio-Convert A/S. The company does not currently derive income from product sales, licensing, or services, as its operations are centered on research, development, and acquisition of preclinical-stage biotech assets.

The company operates through the following segments: Orocidin A/S, Bio-Convert A/S, and NoviThera ApS.

• Orocidin A/S: This segment is a Danish preclinical-stage biotechnology company developing next-generation therapies for periodontitis, a severe gum disease that can lead to tooth loss and systemic health complications. The company’s lead product, QR-01, is a proprietary medical treatment designed for topical buccal application with prolonged adhesion and controlled release of the active ingredient. Orocidin A/S has completed a 14-day toxicology study in hamsters showing high tolerance and no adverse reactions, along with two efficacy studies in beagle dogs and Wistar rats demonstrating improvements in periodontal clinical endpoints and reduced bone loss. The first Phase IIa clinical trial for QR-01 is anticipated to begin in the first half of 2027 at the University of Copenhagen in Denmark.
• Bio-Convert A/S: This segment is a Denmark-based preclinical-stage biotechnology company focused on revolutionizing the treatment of oral leukoplakia (OLK), a potentially pre-cancerous oral condition with up to a 30% conversion rate to oral cancer. The company’s lead compound, QR-02, is a novel proprietary mucoadhesive oral topical formulation designed to treat and reduce dysplasia levels, offering a potential curative alternative to surgery, which is currently the only approved intervention. Bio-Convert A/S has obtained a toxicity waiver from the Danish Medicine Agency (DKMA) for QR-02 and is finalizing its GMP product, expected to be completed by December 2026 in Germany, with Phase IIa clinical trials in Europe anticipated to start in the first half of 2027. The formulation provides antitumor and antiviral effects, aiming to enable more precise and efficient treatment compared to existing methods.
• NoviThera ApS: This segment was formed in October 2025 to research and develop monoclonal antibody (MaB) therapy for the treatment of psoriasis, an immune-mediated inflammatory disease causing keratinocyte hyperproliferation and chronic skin lesions. The company’s lead compound, QR-04, aims to cure or prevent psoriasis, addressing a significant unmet medical need given the absence of a permanent cure in current therapies. NoviThera recently completed a study in mice demonstrating biological proof of concept for QR-04, supporting further development toward preclinical and clinical stages. The company is led by Allan Wehnert, who also serves as CEO of Orocidin A/S and Bio-Convert A/S, under a structure where Alteral Therapeutics holds a 49.9% ownership interest and Nordicus Partners Corporation retains 50.1%.

Nordicus Partners Corporation operates in the highly competitive biotechnology industry, particularly within the niche of oral and dermatological therapeutics, where it faces competition from both large pharmaceutical companies and specialized biotech firms developing similar treatments for periodontitis, oral leukoplakia, and psoriasis. The company differentiates itself through its Nordic-focused acquisition strategy, targeting early-stage innovations with strong scientific foundations and leveraging its value creation process to accelerate development milestones. Its competitive advantage lies in identifying undervalued preclinical assets, providing strategic and operational support, and structuring transactions to maximize upside potential through phased development and strategic exits, all while maintaining a lean operational model focused on value infusion rather than internal drug discovery from scratch.

Nordicus Partners Corporation serves patients suffering from periodontitis, oral leukoplakia, and psoriasis, with its therapeutic candidates intended for individuals diagnosed with these conditions who currently have limited or unsatisfactory treatment options. The company’s ultimate customers are expected to be patients and healthcare systems seeking effective, safe, and durable solutions for chronic oral and inflammatory diseases. While specific customer names such as hospitals or clinics are not disclosed in the filing, the target end-users include individuals seeking relief from gum disease, pre-cancerous oral lesions, and chronic skin inflammation, positioning the company’s future products within the global pharmaceutical and specialty medicine markets.